Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant targeted proteins for biotherapy.

A Ahmad1, K Law

  • 1Biotherapeutics, Inc., Franklin, TN.

Molecular Biotherapy
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of the [Formula: see text] production cross section in the all-jets final state in pp collisions at [Formula: see text][Formula: see text].

The European physical journal. C, Particles and fields·2016
Same author

Event generator tunes obtained from underlying event and multiparton scattering measurements.

The European physical journal. C, Particles and fields·2016
Same author

Endoxifen, a New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen.

Clinical and translational science·2016
Same author

Rational Design and Synthesis of Biologically Active Disubstituted 2(3H) Furanones and Pyrrolone Derivatives as Potent and Safer Non Steroidal Anti-inflammatory Agents.

Anti-inflammatory & anti-allergy agents in medicinal chemistry·2016
Same author

The impact of age on nodal metastases and survival in gastric cancer.

The Journal of surgical research·2016
Same author

Frequency of kidney diseases and clinical indications of pediatric renal biopsy: A single center experience.

Indian journal of nephrology·2016

Recombinant DNA technology enhances biotherapies by engineering toxins and antibodies. Genetically modified proteins show reduced toxicity and immunogenicity, offering improved treatments for diseases like cancer and AIDS.

Area of Science:

  • Biotechnology and Genetic Engineering
  • Immunology
  • Molecular Biology

Background:

  • Existing biotherapies face challenges like nonspecific toxicity and rapid immune clearance.
  • Recombinant DNA technology offers a method to overcome these limitations by altering therapeutic molecules.

Purpose of the Study:

  • To explore the advantages of genetically engineered proteins in biotherapy.
  • To evaluate the potential of modified toxins, antibodies, and fusion proteins for treating various diseases.

Main Methods:

  • Utilizing recombinant techniques to modify toxins, monoclonal antibodies, and effector molecules.
  • Developing fusion proteins combining functional domains of different molecules.
  • Creating chimeric antibodies and hybrid hybridomas for targeted therapeutic effects.

Related Experiment Videos

Main Results:

  • Genetically engineered toxins exhibit reduced nonspecific toxicity and slower immune clearance compared to native forms.
  • Fusion proteins and chimeric antibodies demonstrate improved biologic properties and reduced immunogenicity in humans.
  • Hybrid hybridomas enable targeted delivery of effector cells or toxins to tumor cells.

Conclusions:

  • Recombinant proteins offer significant advantages over traditional biotherapeutic agents.
  • Engineered molecules show promise for treating cancer, acquired immunodeficiency syndrome (AIDS), and autoimmune diseases.
  • Further development of these advanced biotherapeutics is expected to revolutionize treatment paradigms.